Last reviewed · How we verify

Baycrest — Portfolio Competitive Intelligence Brief

Baycrest pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CHG antiseptic body cleanser CHG antiseptic body cleanser marketed Antimicrobial antiseptic Bacterial cell membrane Infection Prevention / Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. B. Braun Ltd. Centre of Excellence Infection Control · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Baycrest:

Cite this brief

Drug Landscape (2026). Baycrest — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/baycrest. Accessed 2026-05-14.

Related